Skip to main content

Lower-dose chemotherapy benefits older, frail patients with advanced gastroesophageal cancer

A lower-dose, less-toxic regimen of oxaliplatin and capecitabine conferred comparable PFS as the higher-dose regimen among frail and/or elderly patients with advanced gastroesophageal cancer, according to results from the randomized phase 3 GO2 trial scheduled for presentation at ASCO Annual Meeting.

No Comments yet!

Your Email address will not be published.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2022 Esophageal Cancer Education Foundation- by domino